U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Biotech investors often chase early-stage companies in the hope that a single breakthrough trial will deliver massive returns ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...

FAR Biotech, a computational drug discovery company, has officially relocated to Wisconsin. The move marks a significant milestone for the company, which is collaborating with the University ...